Nicola Ferri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1868106/publications.pdf

Version: 2024-02-01

		81900	110387
170	5,421	39	64
papers	citations	h-index	g-index

178	178	178	7082
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications. Cardiovascular Research, 2023, 118, 3288-3304.	3.8	57
2	PCSK9 promotes arterial medial calcification. Atherosclerosis, 2022, 346, 86-97.	0.8	14
3	Nutrition Intervention and Cardiovascular Disease. Nutrients, 2022, 14, 1435.	4.1	2
4	NMR, LC-MS Characterization of Rydingia michauxii Extracts, Identification of Natural Products Acting as Modulators of LDLR and PCSK9. Molecules, 2022, 27, 2256.	3.8	2
5	Evaluation of the effects of natural isoquinoline alkaloids on low density lipoprotein receptor (LDLR) and proprotein convertase subtilisin/kexin type 9 (PCSK9) in hepatocytes, as new potential hypocholesterolemic agents. Bioorganic Chemistry, 2022, 121, 105686.	4.1	5
6	Mitochondrial depletion of glutaredoxin 2 induces metabolic dysfunction-associated fatty liver disease in mice. Redox Biology, 2022, 51, 102277.	9.0	13
7	Impact of Soy Î²-Conglycinin Peptides on PCSK9 Protein Expression in HepG2 Cells. Nutrients, 2022, 14, 193.	4.1	9
8	Effect of REL-1017 (Esmethadone) on Cholesterol, Triglycerides, PCSK9, and hs-CRP in a Phase 2a Double-Blind Randomized Trial in Patients with MDD. CNS Spectrums, 2022, 27, 246-247.	1.2	0
9	The Metabolic Activation of Sofosbuvir Is Impaired in an Experimental Model of NAFLD. Biology, 2022, 11, 693.	2.8	1
10	Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice. Pharmaceutics, 2022, 14, 1120.	4.5	29
11	Proteolysis Targeting Chimeric Molecules: Tuning Molecular Strategies for a Clinically Sound Listening. International Journal of Molecular Sciences, 2022, 23, 6630.	4.1	8
12	Off-label use of reduced dose direct oral factor Xa inhibitors in subjects with atrial fibrillation: a review of clinical evidence. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 334-345.	3.0	9
13	Drugâ€“Drug Interaction with DOACs. , 2021, , 41-69.		0
14	Phage display for targeting PCSK9. EBioMedicine, 2021, 65, 103267.	6.1	1
15	Lipid Lowering Drugs: Present Status and Future Developments. Current Atherosclerosis Reports, 2021, 23, 17.	4.8	41
16	PCSK9 Induces Rat Smooth Muscle Cell Proliferation and Counteracts the Pleiotropic Effects of Simvastatin. International Journal of Molecular Sciences, 2021, 22, 4114.	4.1	4
17	Proprotein Convertase Subtilisin/Kexin Type 9. American Journal of Pathology, 2021, 191, 1385-1397.	3.8	62
18	The Modulation of PCSK9 and LDLR by Supercritical CO2 Extracts of Mentha longifolia and Isolated Piperitone Oxide, an In Vitro Study. Molecules, 2021, 26, 3886.	3.8	2

#	Article	IF	Citations
19	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases â€“ A position paper from the International Lipid Expert Panel (ILEP). Progress in Cardiovascular Diseases, 2021, 67, 40-52.	3.1	39
20	Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosisâ€”The IMPROVE Study. Biomedicines, 2021, 9, 841.	3.2	6
21	The Emerging Role of Nutraceuticals in Cardiovascular Calcification: Evidence from Preclinical and Clinical Studies. Nutrients, 2021, 13, 2603.	4.1	4
22	Angiopoietin-like 3 and subclinical peripheral arterial disease: Evidence from the Brisighella Heart Study. European Journal of Preventive Cardiology, 2020, 27, 2251-2254.	1.8	12
23	PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma. Journal of Clinical Medicine, 2020, 9, 3134.	2.4	19
24	Impact of bariatric surgery-induced weight loss on circulating PCSK9 levels in obese patients. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 2372-2378.	2.6	5
25	Lipoprotein(a) and PCSK9 inhibition: clinical evidence. European Heart Journal Supplements, 2020, 22, L53-L56.	0.1	20
26	Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9. American Journal of Pathology, 2020, 190, 2226-2236.	3.8	26
27	Sex-specific predictors of PCSK9 levels in a European population: The IMPROVE study. Atherosclerosis, 2020, 309, 39-46.	0.8	29
28	Current Evidence and Future Perspectives on Pharmacological Treatment of Calcific Aortic Valve Stenosis. International Journal of Molecular Sciences, 2020, 21, 8263.	4.1	24
29	Depression and cardiovascular riskâ€”association among Beck Depression Inventory, PCSK9 levels and insulin resistance. Cardiovascular Diabetology, 2020, 19, 187.	6.8	31
30	Naturally Occurring PCSK9 Inhibitors. Nutrients, 2020, 12, 1440.	4.1	43
31	Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies. European Heart Journal Supplements, 2020, 22, E64-E67.	0.1	9
32	Clinical Pharmacology of Statins: an Update. Current Atherosclerosis Reports, 2020, 22, 26.	4.8	31
33	Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. Drugs, 2020, 80, 1065-1083.	10.9	22
34	l-Arginine prevents inflammatory and pro-calcific differentiation of interstitial aortic valve cells. Atherosclerosis, 2020, 298, 27-35.	0.8	16
35	Cytotoxic performances of new anionic cyclometalated Pt(II) complexes bearing chelated O^O ligands. Applied Organometallic Chemistry, 2020, 34, e5455.	3.5	12
36	Exploring the Anticancer Potential of Diiron Bis-cyclopentadienyl Complexes with Bridging Hydrocarbyl Ligands: Behavior in Aqueous Media and In Vitro Cytotoxicity. Organometallics, 2020, 39, 645-657.	2.3	38

#	Article	IF	Citations
37	Cholesterol-Lowering Action of a Novel Nutraceutical Combination in Uremic Rats: Insights into the Molecular Mechanism in a Hepatoma Cell Line. Nutrients, 2020, 12, 436.	4.1	11
38	Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia. Pharmacological Research, 2020, 153, 104653.	7.1	54
39	Fucus vesiculosus and Ascophyllum nodosum Ameliorate Liver Function by Reducing Diet-Induced Steatosis in Rats. Marine Drugs, 2020, 18, 62.	4.6	19
40	Himalayan Nettle Girardinia diversifolia as a Candidate Ingredient for Pharmaceutical and Nutraceutical Applicationsâ€"Phytochemical Analysis and In Vitro Bioassays. Molecules, 2020, 25, 1563.	3.8	21
41	Clinical approach to the inflammatory etiology of cardiovascular diseases. Pharmacological Research, 2020, 159, 104916.	7.1	56
42	Monofunctional Pt^{II} Complexes Based on 8â€Aminoquinoline: Synthesis and Pharmacological Characterization. European Journal of Inorganic Chemistry, 2019, 2019, 3389-3395.	2.0	18
43	Differential effects of red yeast rice, Berberis aristata and Morus alba extracts on PCSK9 and LDL uptake. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 1245-1253.	2.6	16
44	Identification of the first enantiopure Rac1â€"Tiam1 proteinâ€"protein interaction inhibitor and its optimized synthesis via phosphine free remote group directed hydroarylation. MedChemComm, 2019, 10, 310-314.	3.4	4
45	Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2019, 11, 120.	3.4	43
46	Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels â€" experimental and clinical approaches with lipid-lowering agents. European Journal of Preventive Cardiology, 2019, 26, 930-949.	1.8	64
47	Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals. European Journal of Preventive Cardiology, 2019, 26, 578-588.	1.8	36
48	PCSK9 as a PositiveÂModulator of Platelet Activation. Journal of the American College of Cardiology, 2018, 71, 952-954.	2.8	60
49	PCSK9 induces a pro-inflammatory response in macrophages. Scientific Reports, 2018, 8, 2267.	3.3	166
50	Present therapeutic role of cholesteryl ester transfer protein inhibitors. Pharmacological Research, 2018, 128, 29-41.	7.1	45
51	PCSK9 antagonists and inflammation. Atherosclerosis, 2018, 268, 235-236.	0.8	15
52	Peptide modulators of Rac1/Tiam1 proteinâ€protein interaction: An alternative approach for cardiovascular diseases. Peptide Science, 2018, 110, e23089.	1.8	21
53	The Brown Algae Fucus vesiculosus and Ascophyllum nodosum Reduce Metabolic Syndrome Risk Factors: A Clinical Study. Natural Product Communications, 2018, 13, 1934578X1801301.	0.5	11
54	Leaf extract of morus alba reduces the expression of proprotein convertase subtilisin kexin type 9 (PCSK9) in HEPG2 cell line. Atherosclerosis, 2018, 275, e55.	0.8	0

#	Article	IF	Citations
55	PCSK9 Involvement in Aortic Valve Calcification. Journal of the American College of Cardiology, 2018, 72, 3225-3227.	2.8	34
56	Leptin and resistin affect PCSK9 expression: In vitro and in vivo evidence. Atherosclerosis, 2018, 275, e18.	0.8	0
57	Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2018, 1863, 991-997.	2.4	14
58	From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. European Journal of Preventive Cardiology, 2018, 25, 1843-1851.	1.8	19
59	Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?. Annals of Medicine, 2018, 50, 461-484.	3.8	28
60	Angiopoietin-Like 3 (ANGPTL3) and Atherosclerosis: Lipid and Non-Lipid Related Effects. Journal of Cardiovascular Development and Disease, 2018, 5, 39.	1.6	36
61	Bococizumab for the treatment of hypercholesterolaemia. Expert Opinion on Biological Therapy, 2017, 17, 237-243.	3.1	20
62	In vitro anticancer activity evaluation of new cationic platinum(II) complexes based on imidazole moiety. Bioorganic and Medicinal Chemistry, 2017, 25, 1907-1913.	3.0	29
63	Methanethiosulfonate derivatives as ligands of the STAT3-SH2 domain. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 337-344.	5.2	8
64	A fieldâ€based disparity analysis of new 1,2,5â€oxadiazole derivatives endowed with antiproliferative activity. Chemical Biology and Drug Design, 2017, 90, 820-839.	3.2	11
65	Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study. Journal of the American Heart Association, 2017, 6, .	3.7	66
66	Fibronectin Type III Domainâ€“Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2660-2669.	3.6	42
67	Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages. Atherosclerosis, 2017, 256, 1-6.	0.8	98
68	Geranylgeraniol prevents the simvastatin-induced PCSK9 expression: Role of the small G protein Rac1. Pharmacological Research, 2017, 122, 96-104.	7.1	11
69	PPAR-Î± agonists are still on the rise: an update on clinical and experimental findings. Expert Opinion on Investigational Drugs, 2017, 26, 593-602.	4.1	44
70	The Glycolytic Enzyme PFKFB3 Is Involved in Estrogen-Mediated Angiogenesis via GPER1. Journal of Pharmacology and Experimental Therapeutics, 2017, 361, 398-407.	2.5	53
71	An inÂvivo active 1,2,5-oxadiazole Pt(II) complex: A promising anticancer agent endowed with STAT3 inhibitory properties. European Journal of Medicinal Chemistry, 2017, 131, 196-206.	5.5	37
72	Influence of PCSK9 on biological behavior of mouse smooth muscle cells. Atherosclerosis, 2017, 263, e63.	0.8	0

#	Article	IF	Citations
73	Circulating levels of PCSK9 and arterial stiffness in a large population sample: Data from the brisighella heart study. Atherosclerosis, 2017, 263, e105-e106.	0.8	0
74	A new role for PCSK9 as a co-activator of platelet reactivity. Atherosclerosis, 2017, 263, e29.	0.8	1
75	Leptin and resistin affect PCSK9 expression via STAT3 involvement. Atherosclerosis, 2017, 263, e70-e71.	0.8	0
76	New sulfurated derivatives of cinnamic acids and rosmaricine as inhibitors of STAT3 and NF-ÎºB transcription factors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 1012-1028.	5.2	8
77	Plasma PCSK9 levels and lipoprotein distribution are preserved in patients with severe hypoalphalipoproteinemia. Atherosclerosis, 2017, 263, e91.	0.8	0
78	PCSK9 induces a pro-inflammatory response in macrophages. Atherosclerosis, 2017, 263, e11.	0.8	0
79	Tuning the cytotoxicity of ruthenium(ii) para-cymene complexes by mono-substitution at a triphenylphosphine/phenoxydiphenylphosphine ligand. Dalton Transactions, 2017, 46, 16589-16604.	3.3	42
80	The small heat shock protein B8 (HSPB8) modulates proliferation and migration of breast cancer cells. Oncotarget, 2017, 8, 10400-10415.	1.8	42
81	Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9. Therapeutics and Clinical Risk Management, 2017, Volume 13, 1555-1562.	2.0	18
82	Development of poly(lactideâ€coâ€glycolide) nanoparticles functionalized with a mitochondria penetrating peptide. Journal of Peptide Science, 2017, 23, 182-188.	1.4	9
83	Synthesis of new dithiolethione and methanethiosulfonate systems endowed with pharmaceutical interest. Arkivoc, 2017, 2017, 235-250.	0.5	2
84	Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 315-320.	2.6	47
85	Liver fat accumulation is associated with circulating PCSK9. Annals of Medicine, 2016, 48, 384-391.	3.8	119
86	Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia. Endocrine, 2016, 54, 588-601.	2.3	58
87	TNF-alpha induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line in a SOCS-3-dependent manner. Atherosclerosis, 2016, 252, e197-e198.	0.8	1
88	Smooth muscle cells PCSK9 knock-out exhibit an impaired response to PDGF stimulation. Atherosclerosis, 2016, 252, e200.	0.8	0
89	The absence of PCSK9 determines a lower neointimal formation in response to perivascular carotid collar placement. Atherosclerosis, 2016, 252, e233-e234.	0.8	0
90	PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. Atherosclerosis, 2016, 253, 214-224.	0.8	78

#	Article	IF	Citations
91	In vitro evidence of a pro-inflammatory action of PCSK9 in THP-1-derived macrophages. Atherosclerosis, 2016, 252, e220.	0.8	0
92	Pharmacokinetics interactions of monoclonal antibodies. Pharmacological Research, 2016, 111, 592-599.	7.1	78
93	Circulating PCSK9 Levels are Associated with the Hepatic Fat in Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 2016, 64, S492.	3.7	0
94	Disruption of ArhGAP15 results in hyperactive Rac1, affects the architecture and function of hippocampal inhibitory neurons and causes cognitive deficits. Scientific Reports, 2016, 6, 34877.	3.3	58
95	Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line. Journal of Biological Chemistry, 2016, 291, 3508-3519.	3.4	93
96	Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence. Translational Research, 2016, 173, 19-29.	5.0	45
97	Fibronectin extra domain A stabilises atherosclerotic plaques in apolipoprotein E and in LDL-receptor-deficient mice. Thrombosis and Haemostasis, 2015, 114, 186-197.	3.4	21
98	Naturally occurring PDGF receptor inhibitors with potential anti-atherosclerotic properties. Vascular Pharmacology, 2015, 70, 1-7.	2.1	26
99	Aliskiren inhibits prorenin-induced human aortic smooth muscle cell migration. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 284-291.	1.7	4
100	Human megakaryocytes confer tissue factor to a subset of shed platelets to stimulate thrombin generation. Thrombosis and Haemostasis, 2015, 114, 579-592.	3.4	34
101	The absence of the EDA alternative spliced isoform of fibronectin promotes smooth muscle cells migration and results in neo-intimal hyperplasia. Atherosclerosis, 2015, 241, e45.	0.8	0
102	STAT3 inhibition induces PCSK9 in hepatic cell line: possible involvement in hypertriglyceridemia associated with insulin resistance. Atherosclerosis, 2015, 241, e46-e47.	0.8	0
103	Promising antiproliferative platinum(II) complexes based on imidazole moiety: synthesis, evaluation in HCT-116 cancer cell line and interaction with Ctr-1 Met-rich domain. Bioorganic and Medicinal Chemistry, 2015, 23, 2538-2547.	3.0	21
104	Dipeptide Nanotubes Containing Unnatural Fluorine-Substituted Î²^{2,3}-Diarylamino Acid and <scp>l</scp>-Alanine as Candidates for Biomedical Applications. Organic Letters, 2015, 17, 4468-4471.	4.6	50
105	Liver fat accumulation is associated with circulating PCSK9 levels. Digestive and Liver Disease, 2015, 47, e230.	0.9	0
106	Farnesyltransferase inhibitors: CAAX mimetics based on different biaryl scaffolds. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2924-2927.	2.2	15
107	Clinical evidence of statin therapy in non-dyslipidemic disorders. Pharmacological Research, 2014, 88, 20-30.	7.1	20
108	2-Amino-3-(phenylsulfanyl)norbornane-2-carboxylate: An Appealing Scaffold for the Design of Rac1â€“Tiam1 Proteinâ€“Protein Interaction Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 2953-2962.	6.4	31

#	Article	IF	Citations
109	Proprotein convertase subtilisin/kexin type 9 deficient mice are protected from neointima formation in carotid artery injury model. Atherosclerosis, 2014, 235, e21-e22.	0.8	0
110	Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties. Drugs, 2013, 73, 1681-1709.	10.9	118
111	Nitric Oxide-Donating Atorvastatin Attenuates Neutrophil Recruitment During Vascular Inflammation Independent of Changes in Plasma Cholesterol. Cardiovascular Drugs and Therapy, 2013, 27, 211-219.	2.6	9
112	Drug attrition during pre-clinical and clinical development: Understanding and managing drug-induced cardiotoxicity. , 2013, 138, 470-484.		161
113	Cytotoxic effect of (1-methyl-1 H -imidazol-2-yl)-methanamine and its derivatives in Pt II complexes on human carcinoma cell lines: A comparative study with cisplatin. Bioorganic and Medicinal Chemistry, 2013, 21, 2379-2386.	3.0	23
114	3-Aryl-N-aminoylsulfonylphenyl-1H-pyrazole-5-carboxamides: a new class of selective Rac inhibitors. MedChemComm, 2013, 4, 537.	3.4	26
115	Cross-talk between EGFR and T-cadherin: EGFR activation promotes T-cadherin localization to intercellular contacts. Cellular Signalling, 2013, 25, 1044-1053.	3.6	12
116	Pharmacological Modulation of Small GTPases in Cardiovascular Diseases. Journal of Cardiovascular Pharmacology, 2013, 62, 329-330.	1.9	1
117	Role of Small GTPase Protein Rac1 in Cardiovascular Diseases. Journal of Cardiovascular Pharmacology, 2013, 62, 425-435.	1.9	30
118	Proprotein Convertase Subtilisin/Kexin Type 9: From the Discovery to the Development of New Therapies for Cardiovascular Diseases. Scientifica, 2012, 2012, 1-21.	1.7	10
119	Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis, 2012, 220, 381-386.	0.8	212
120	Upregulation of lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) expression in human endothelial cells by modified high density lipoproteins. Biochemical and Biophysical Research Communications, 2012, 428, 230-233.	2.1	23
121	Chemotactic effect of prorenin on human aortic smooth muscle cells: a novel function of the (pro)renin receptor. Cardiovascular Research, 2012, 95, 366-374.	3.8	27
122	AMP-activated protein kinase and the control of smooth muscle cell hyperproliferation in vascular disease. Vascular Pharmacology, 2012, 56, 9-13.	2.1	20
123	Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) by 15-lipoxygenase-modified LDL in endothelial cells. Atherosclerosis, 2011, 214, 331-337.	0.8	36
124	Muscle cells and motoneurons differentially remove mutant SOD1 causing familial amyotrophic lateral sclerosis. Journal of Neurochemistry, 2011, 118, 266-280.	3.9	55
125	17-AAG increases autophagic removal of mutant androgen receptor in spinal and bulbar muscular atrophy. Neurobiology of Disease, 2011, 41, 83-95.	4.4	55
126	Synthesis, structural, and biological evaluation of bis-heteroarylmaleimides and bis-heterofused imides. Bioorganic and Medicinal Chemistry, 2011, 19, 5291-5299.	3.0	24

#	Article	IF	Citations
127	Thiazole- and imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5408-5412.	2.2	20
128	Aliskiren reduces prorenin receptor expression and activity in cultured human aortic smooth muscle cells. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2011, 12, 469-474.	1.7	28
129	Fibrillar Collagen Inhibits Cholesterol Biosynthesis in Human Aortic Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1631-1637.	2.4	1
130	Everolimus Inhibits Monocyte/Macrophage Migration in Vitro and Their Accumulation in Carotid Lesions of Cholesterol-Fed Rabbits. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 419-425.	2.5	52
131	New Ras CAAX mimetics: Design, synthesis, antiproliferative activity, and RAS prenylation inhibition. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5500-5504.	2.2	12
132	Synthetic peptides containing a conserved sequence motif of the Id protein family modulate vascular smooth muscle cell phenotype. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6298-6302.	2.2	20
133	Differential Processing of Î±- and Î²-Defensin Precursors by Matrix Metalloproteinase-7 (MMP-7). Journal of Biological Chemistry, 2009, 284, 8301-8311.	3.4	49
134	Virtual Screening Approach for the Identification of New Rac1 Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 4087-4090.	6.4	96
135	Antiproliferative effects on human tumor cells and rat aortic smooth muscular cells of 2,3-heteroarylmaleimides and heterofused imides. Bioorganic and Medicinal Chemistry, 2008, 16, 1691-1701.	3.0	23
136	Fluvastatin Synergistically Improves the Antiproliferative Effect of Everolimus on Rat Smooth Muscle Cells by Altering p27^{Kip1}/Cyclin E Expression. Molecular Pharmacology, 2008, 74, 144-153.	2.3	18
137	Inhibition of Smooth Muscle Cell Migration and Proliferation by Statins. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2008, 8, 122-140.	0.5	4
138	Simvastatin Reduces MMP1 Expression in Human Smooth Muscle Cells Cultured on Polymerized Collagen by Inhibiting Rac1 Activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1043-1049.	2.4	39
139	PO9-218 IN VITRO AND IN VIVO STUDIES OF ANTIATHEROSCLEROTIC PROPERTIES OF EVEROLIMUS. Atherosclerosis Supplements, 2007, 8, 71.	1.2	0
140	Peptidomimetic inhibitors of farnesyltransferase with high in vitro activity and significant cellular potency. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6192-6196.	2.2	20
141	Are pleiotropic effects of statins real?. Vascular Health and Risk Management, 2007, 3, 611-3.	2.3	21
142	Tu-W18:6 Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting RAC1 activation. Atherosclerosis Supplements, 2006, 7, 157.	1.2	0
143	Tu-P7:271 Selective inhibition on gelatinase A and B versus collagenase-1 by an amino-sulphone-hydroxamate derivative. Atherosclerosis Supplements, 2006, 7, 244.	1.2	0
144	Biomarkers for atherosclerosis: pathophysiological role and pharmacological modulation. Current Opinion in Lipidology, 2006, 17, 495-501.	2.7	26

#	Article	IF	Citations
145	Isothiazoles. Part XV. A mild andÂefficient synthesis ofÂnew antiproliferative 5-sulfanylsubstituted 3-alkylaminoisothiazole 1,1-dioxides. European Journal of Medicinal Chemistry, 2006, 41, 675-682.	5.5	13
146	Integrin-Mediated Transcriptional Activation of Inhibitor of Apoptosis Proteins Protects Smooth Muscle Cells Against Apoptosis Induced by Degraded Collagen. Circulation Research, 2006, 98, 1490-1497.	4.5	39
147	Isothiazole dioxide derivative 6n inhibits vascular smooth muscle cell proliferation and protein farnesylation. Biochemical Pharmacology, 2005, 70, 1735-1743.	4.4	7
148	Thematic Review Series: The Immune System and Atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease. Journal of Lipid Research, 2005, 46, 1081-1092.	4.2	145
149	Lipid-modified proteins as biomarkers for cardiovascular disease: a review. Biomarkers, 2005, 10, 219-237.	1.9	29
150	Beyond the Endothelium. Circulation Research, 2004, 94, 706-708.	4.5	26
151	Role of Discoidin Domain Receptors 1 and 2 in Human Smooth Muscle Cell-Mediated Collagen Remodeling. American Journal of Pathology, 2004, 164, 1575-1585.	3.8	158
152	Cleavage of Focal Adhesion Kinase in Vascular Smooth Muscle Cells Overexpressing Membrane-Type Matrix Metalloproteinases. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 839-844.	2.4	25
153	Ajoene, a garlic compound, inhibits protein prenylation and arterial smooth muscle cell proliferation. British Journal of Pharmacology, 2003, 138, 811-818.	5.4	37
154	Fas and Fas-Associated Death Domain Protein Regulate Monocyte Chemoattractant Protein-1 Expression by Human Smooth Muscle Cells Through Caspase- and Calpain-Dependent Release of Interleukin-1Î±. Circulation Research, 2003, 93, 515-522.	4.5	35
155	An NF-ÎºB-dependent Transcriptional Program Is Required for Collagen Remodeling by Human Smooth Muscle Cells. Journal of Biological Chemistry, 2003, 278, 19757-19764.	3.4	33
156	Efficient Expression of Exogenous Genes in Primary Vascular Cells Using IRES-Based Retroviral Vectors. BioTechniques, 2002, 32, 830-843.	1.8	41
157	Effect of S(â^') perillic acid on protein prenylation and arterial smooth muscle cell proliferationâ^†2â^†This research was partially supported by Institut of Recherches Internationales Servier, Paris, France. N. Ferri, L. Arnaboldi, and A. Corsini are also partially supported by a grant from the Ministero		

#	Article	IF	Citations
163	3.P.247 Farnesol and geranylgeraniol prevent the inhibition elicited by simvastatin on proliferation and actin polymerization in rat arterial smooth muscle cells. Atherosclerosis, 1997, 134, 250.	0.8	0
164	3.P.244 L(â^') perillic acid inhibits protein prenylation and the growth of rat and human arterial myocytes â€œin vitroâ€• Atherosclerosis, 1997, 134, 249.	0.8	0
165	3.P.239 Pharmacological control of protein prenylation and arterial smooth muscle cell proliferation. Atherosclerosis, 1997, 134, 248.	0.8	0
166	1.P.172 Antiatherosclerotic activities of mibefradil in cell culture models. Atherosclerosis, 1997, 134, 53.	0.8	0
167	Effects of four antiepileptic drugs on sleep and waking in the rat under both light and dark phases. Pharmacology Biochemistry and Behavior, 1996, 53, 559-565.	2.9	13
168	Role of Isoprenoids In the Growth-Factor Signal Transduction and their Pharmacological Modulation. Medical Science Symposia Series, 1996, , 103-110.	0.0	0
169	Effects of repeated administration of selective adenosine A1 and A2A receptor agonists on pentylenetetrazole-induced convulsions in the rat. European Journal of Pharmacology, 1995, 294, 383-389.	3.5	55
170	The dopamine D1 receptor agonists, A68930 and SKF 38393, induce arousal and suppress REM sleep in the rat. European Journal of Pharmacology, 1993, 235, 83-87.	3.5	66